In summary, the incorporation of APOA-I into existing biomarker panels may improve diagnostic sensitivity and specificity for AD, and early therapeutic interventions using APOA-I-targeted agents may represent a promising advancement in AD management. Here, APOA1 is linked to Alzheimer disease.